NephroPlus, the only publicly listed dialysis company in Asia, is shifting its focus from India to become a global dialysis network. Currently the fifth-largest dialysis provider worldwide, the company operates over 520 clinics across multiple countries including India, the Philippines, Saudi Arabia, Uzbekistan, and Nepal. Its international revenue surged from 12% in FY23 to nearly 42% in FY26, driven by acquisitions and partnerships. NephroPlus aims to open 40–50 clinics annually in India and 15–16 clinics in the Philippines, with plans for further international expansion. In FY26, the company reported a revenue of ₹998.8 crore (approximately $120 million USD), a 32.2% increase year-on-year, while treatment volumes rose 16.6% to 3.84 million sessions. The pricing for dialysis treatments is notably higher in international markets, with the Philippines charging around $110 per session compared to $22–25 in India, enhancing profitability. Despite aggressive overseas expansion, NephroPlus continues to prioritize India, where demand for dialysis is growing due to an estimated 220,000 new end-stage renal disease patients annually.